This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceuticalcompanies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.
Opportunities in Drug Repurposing There is great potential for drug repurposing to unlock treatments for rare and neglected diseases, where traditional drug development is too costly. Pharma companies are often rich with valuable chemical libraries and expertise, while academics bring emerging disease biology knowledge.
They have established multiple collaborations with renowned pharmaceuticalcompanies and successfully developed the AI software platforms Makya™ for new drug design and Spaya™ for synthesis planning.
A recent editorial by Dean Brown in J Med Chem and follow-up posts by Keith Hornberger and Derek Lowe prompted me to think about how we train computational chemists and cheminformaticians for careers in drug discovery. It also brought to mind some unique differences between how computationalchemistry is practiced in biotech and pharma.
Founded in 2011, NuChem Sciences delivers expert integrated and standalone discovery solutions across medicinal, synthetic, scale-up, process and computationalchemistry, as well as DMPK, in vitro biology and in vivo pharmacology.
” Arthur Oubrie, Chief Scientific Officer of Lead Pharma, added: “This is the second project we partner with one of the largest pharmaceuticalcompanies under our Discover, Design and Deliver platform. ” About Immune Mediated Diseases. A wide range of human diseases is driven by deregulated immune function.
The premise at the time was that putting computationalchemistry in the primary position for new molecule ideation would upend the drug discovery paradigm. set up a “virtual project team,” leverage Schrödinger scientists to lead computationalchemistry, and do all the wet work at CROs. It did just that.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content